TGFB1 and neoplasm: Emerging preclinical evidence demonstrates that losartan can effectively modulate the tumour microenvironment (TME) by inhibiting transforming growth factor‐β (TGF‐β) signalling, reducing stromal stiffness and improving vascular perfusion.